European patent granted relevant to Idogen’s cell therapy for hemophilia A
Idogen AB (”Idogen”) announces that it has received notice that the European Patent Office (”EPO”) will grant a European patent, protecting the company’s tolerogenic cell therapy’s application to the severe bleeding disorder (hemophilia A). After the formal granting on July 07, 2021, the patent will be validated in key European countries. The granting of this patent strengthens the company’s patent portfolio and will provide additional protection tothe broader patent application for Idogen´s platform technology which in December 2020 was extended via an International (PCT) application.
The European Patent Office issued in February 2021 a “Notice of intention to grant” and has now communicated that on July 07, 2021, it will formally grant Idogen’s Patent Application relating to the application of the company’s tolerogenic cell therapy to the severe bleeding disorder (hemophilia A). This patent application was submitted in 2016 and the grant of this patent (EP3270953B) will protect this technical space until 2036. The patent will be officially validated in a number of strategically interesting countries in Europe. A similar patent application is pending in the USA.
The granted patent will provide important complementary protection to that sought via the International (PCT) application for Idogen´s new, innovative method for cell therapy that was filed in December 2020. That patent application will, following grant, provide the company with a patent protection and market exclusivity until 2040.
“We are very happy to receive this very positive news confirming the patent grant from the European Patent Office. The patent protects Idogen´s technology to prevent the production by the immune system of neutralizing (inhibiting) antibodies against treatment with blood factors such as Factor VIII (FVIII). This patent will provide additional protection and strengthen the company´s patent portfolio for IDO 8, for which we intend to initiate clinical studies during the second half of 2021”, says Anders Karlsson CEO at Idogen.
For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Phone: +46 70 918 00 10
Email: anders.karlsson@idogen.com
The information was submitted for publication, through the agency of the contact persons set out above, on July 07, 2021.
The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third programme, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment intervention to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care.
Tags: